Q3 2025 Repligen Corp Earnings Call Transcript
Key Points
- Repligen Corp (RGEN) reported an 18% organic growth for the third quarter of 2025, with every franchise achieving double-digit growth.
- The company experienced over 50% growth in its analytics franchise, driven by the successful launch of SoloVPE PLUS.
- Repligen Corp (RGEN) saw strong growth in the Asia Pacific region, with approximately 50% growth, highlighting the success of recent investments in the area.
- The company raised its full-year 2025 revenue guidance, reflecting confidence in its portfolio strength and market position.
- Repligen Corp (RGEN) reported a strong cash position of $749 million, driven by robust operating cash flow performance.
- Repligen Corp (RGEN) noted a headwind from a specific gene therapy customer, impacting growth in the second half of 2025.
- The company experienced a decline in adjusted EBITDA margin by 160 basis points year-over-year, partly due to foreign currency transaction losses.
- Repligen Corp (RGEN) faced challenges in China, with expectations of a slight decline in revenue for the year despite a return to growth in Q3.
- The company reported a $2 million impact from one-time operating expenses related to leadership changes, affecting operating margins.
- Repligen Corp (RGEN) highlighted that tariffs remain a slight headwind, impacting overall profitability.
Thank you for standing by. My name is Kaylin. I will be your conference operator today. At this time, I would like to welcome everyone to the Repligen Corporation earnings release third quarter of 2025. (Operator Instructions) I would now like to turn the call over to Jacob Johnson, VP of Investor Relations. You may begin.
Thank you, operator, and welcome everyone to our 2025 third quarter report. On this call, we will cover business highlights and financial performance for the three month period ended September 30, 2025. I will provide financial guidance for the full year 2025.
Joining us on the call today are Repligen's President and Chief Executive Officer, Olivier Loeillot; and our Chief Financial Officer, Jason Garland.
As a reminder, the forward-looking statements that we make during this call, including those regarding our business goals and expectations for the financial performance of the company, are subject to risk and uncertainties that may cause actual events or results to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
